Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Fokus Mining Intersects 10 Metres Grading 10.06 G/T At The Galloway Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Alimera Sciences Inc ALIM

Healthcare
Alimera Sciences, Inc. is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic retinal pharmaceuticals. It is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye ... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ALIM)

Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 20, 2024

Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network

GlobeNewswire March 19, 2024

Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results

GlobeNewswire March 7, 2024

Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update

GlobeNewswire February 29, 2024

The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®

GlobeNewswire February 8, 2024

Alimera Completes Recruitment for the Synchronicity Study

GlobeNewswire January 4, 2024

Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 2, 2024

Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 12, 2023

Alimera Appoints Maggie A. Pax to Its Board of Directors

GlobeNewswire November 8, 2023
View More News ››

Opinion & Analysis (NDAQ:ALIM)

Cutting-edge devices and diagnostics deliver drugs and profits: Cantor Fitzgerald's Caroline Corner

George S. Mack July 31, 2015
View More Opinion ››

Bullboard Posts (NDAQ:ALIM)

Answering to the SEC

Allergy Immuno Technologies, Inc. is in the Process of Responding To the SEC's Comments on Its Form 10-SB NEWPORT BEACH...
The Teaser - July 31, 1999
View more Bullboard ››

Forsys Metals Corp

Forsys Metals Corp

Forsys Metals Corp. is a Canada-based company, which is engaged in the business of acquiring, exploring and developing ...
View More »